Hepatocellular carcinoma

Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

Retrieved on: 
Thursday, November 2, 2023
Neoplasm, HCC, NSCLC, PD, Renal cell carcinoma, Therapy, Cancer, ESCC, SCCHN, Head, MSI-H, RCC, Pharmacokinetics, Mesothelioma, Lung cancer, Melanoma, Safety, Hepatocellular carcinoma, TME, Patient, Carcinoma, Neck, Pharmaceutical industry

AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of advanced solid tumors.

Key Points: 
  • AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of advanced solid tumors.
  • The Phase 1 study is a multi-center open-label, dose-escalation, dose-expansion, and a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary efficacy of MT-8421.
  • Approximately 24-30 patients are anticipated to enroll in Part A dose escalation with a starting dose of 32 mcg/kg.
  • “We look forward to this approach providing patient benefit in this first-in-human study.”

CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers

Retrieved on: 
Tuesday, October 31, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, HCC, Society for Immunotherapy of Cancer, NSCLC, Nivolumab, Bladder cancer, Cell adhesion, Phosphorylation, SITC, Immunotherapy, Annual general meeting, Tumor microenvironment, Lung cancer, Safety, Society, Cancer, Hepatocellular carcinoma, Patient, Pharmaceutical industry, Vaccine

Visugromab is currently evaluated in a broad Phase 2 program in combination with anti-PD-1 treatment in multiple solid tumor indications.

Key Points: 
  • Visugromab is currently evaluated in a broad Phase 2 program in combination with anti-PD-1 treatment in multiple solid tumor indications.
  • “The new data for the combination of visugromab with bispecific T-cell engagers provide strong scientific support for a synergistic effect in this novel therapeutic setting.
  • When investigating the involvement of additional cell adhesion pathway components downstream of GDF-15, SHP-1 was identified as a central mediator of GDF-15-related inhibition of T cell adhesion.
  • In addition, CatalYm recently announced an exploratory Phase 2 study , GDFather-NEO ( NCT06059547 ), evaluating visugromab in combination with neoadjuvant immunotherapy in first-line muscle-invasive bladder cancer.

Elevar Therapeutics Names Brian Cunningham Vice President of Sales and Kenneth Rankin Vice President of Market Access, Strengthening Commercial Leadership in Buildup to Launch

Retrieved on: 
Monday, October 23, 2023
FDA, HCC, Greater China, PDUFA, Food, Strategic planning, Incyte, Kutztown University of Pennsylvania, University, Mesothelioma, Bowling Green State University, Regulation of tobacco by the U.S. Food and Drug Administration, Pfizer, Array BioPharma, Cunningham, Business administration, Hepatocellular carcinoma, Football, Therapy, Master of Business Administration, Patient, Communication, Pharmaceutical industry, Management

"The additions of Brian Cunningham and Kenneth Rankin come at an important and exciting time for Elevar, as we position the company for a potential commercial launch in the coming year,” said Elevar Chief Commercial Officer Paul Friel.

Key Points: 
  • "The additions of Brian Cunningham and Kenneth Rankin come at an important and exciting time for Elevar, as we position the company for a potential commercial launch in the coming year,” said Elevar Chief Commercial Officer Paul Friel.
  • “Both possess a wealth of sales and management acumen, and a great understanding of the road ahead for our company.
  • Cunningham joins Elevar from global oncology company Novocure, where he served as the national sales and operations lead for its Central Nervous System Cancers Franchise.
  • He was previously vice president of sales for rare commercial services at Dohmen Life Science Services, and director of Eisai Inc.’s government payer team.

OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody

Retrieved on: 
Monday, October 23, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, OSE, MTD, HCC, Mnemos EP, ESMO, ISIN, Human, European Society for Medical Oncology, CD47, HNSCC, Hackensack Meridian Health, Boehringer Ingelheim, Centre hospitalier, Clinical trial, Immunoglobulin G, Partnership, Oncology, Tumor microenvironment, Hackensack University Medical Center, Cancer, Hepatocellular carcinoma, CHUM, Patient, Mab, Myelocyte, Vaccine, Fine chemical, Pharmaceutical industry, QC

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced solid tumors, have been presented, at the European Society for Medical Oncology conference , held in Madrid, Spain (October 20 – 24, 2023).

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced solid tumors, have been presented, at the European Society for Medical Oncology conference , held in Madrid, Spain (October 20 – 24, 2023).
  • BI 770371 is an IgG1 mAb that recognizes both the V1 and V2 variants of SIRPα.
  • We are very pleased to potentially make our selective SIRPα inhibitor technology available to more patients through this strategic collaboration.
  • The first clinical results of BI 770371 presented at ESMO 2023 conference (Madrid, Abstract #697P ) showed that adverse events were manageable during the on-treatment period, Maximal Tolerated Dose (MTD) has not been reached.

Elevar Therapeutics and Jiangsu Hengrui Pharma Announce Global Commercialization Licensing Agreement for PD-1 Inhibitor Camrelizumab in Combination with Rivoceranib for uHCC

Retrieved on: 
Tuesday, October 17, 2023
Congress, Jiangsu Hengrui Medicine, Food, Hepatocellular carcinoma, Research, Standard of care, BLA, Death, Survival, R, Liver cancer, FDA, ESMO, Therapy, Oncology, Sorafenib, NDA, Regulation of tobacco by the U.S. Food and Drug Administration, European Society for Medical Oncology, PDUFA, Progression-free survival, HCC, Patient, Pharmaceutical industry, Generic drug, Lancet, EU

Under the terms of the agreement, Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales.

Key Points: 
  • Under the terms of the agreement, Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales.
  • In May 2023, a new drug application (NDA) for rivoceranib and a biologics license application (BLA) for camrelizumab were submitted to the U.S. Food and Drug Administration (FDA) for the combination of rivoceranib and camrelizumab as a first-line therapy for uHCC.
  • In January 2023, the combination was approved in China as a first-line treatment for uHCC.
  • Camrelizumab plus rivoceranib significantly prolonged overall survival and progression-free survival, and increased overall response rate versus sorafenib, a standard first-line treatment for uHCC.

Jiangsu Hengrui Pharma and Elevar Therapeutics Announce Global Commercialization Licensing Agreement for PD-1 Inhibitor Camrelizumab in Combination with Rivoceranib for uHCC

Retrieved on: 
Tuesday, October 17, 2023
Congress, Food, Hepatocellular carcinoma, Research, BLA, R, FDA, Sorafenib, Therapy, NDA, Regulation of tobacco by the U.S. Food and Drug Administration, Responses to the COVID-19 pandemic in September 2022, PDUFA, Progression-free survival, HCC, Patient, Pharmaceutical industry, Generic drug, Lancet

Under the terms of the agreement, Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales.

Key Points: 
  • Under the terms of the agreement, Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales.
  • Rivoceranib, under the name apatinib (brand name: Aitan®), is developed by Hengrui Pharma in China.
  • Elevar and Hengrui Pharma presented CARES-310 study results at the September 2022 ESMO Congress and published them in The Lancet on July 24, 2023.
  • Camrelizumab plus rivoceranib significantly prolonged overall survival and progression-free survival, and increased overall response rate versus sorafenib, a standard first-line treatment for uHCC.

First Results of Median Technologies’ iBiopsy® HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress (Oct 20-24, 2023, Madrid, Spain)

Retrieved on: 
Tuesday, October 17, 2023
Other Health, Research, Radiology, Oncology, Medical Devices, Technology, Artificial Intelligence, Clinical Trials, Science, Surgery, Biotechnology, Health, Congress, Diagnosis, Neoplasm, ID, Algorithm, Deep learning, Death, Artery, Translational research, HCC, Survival, Hospital, Cancer, Scan (company), Hepatocellular carcinoma, Liver cancer, CEST, ESMO, Medical device, CDR, Beaujon, Chronic liver disease, AP-HP, European Society for Medical Oncology, Patient, Medical imaging

The study, conducted using data from the PHELICAR clinical data registry (CDR), was led by Pr.

Key Points: 
  • The study, conducted using data from the PHELICAR clinical data registry (CDR), was led by Pr.
  • The primary focus of this study was on the evaluation of Median’s iBiopsy® AI model for the detection of Hepatocellular carcinoma (HCC), ultimately targeting the early diagnosis of HCC.
  • HCC constitutes more than 90% of primary liver cancers, ranking as the third leading cause of death by cancer worldwide1.
  • This notable achievement significantly surpasses the average sensitivity of 69%4 observed among radiologists without AI/ML tech-based computer aided detection.

Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894

Retrieved on: 
Wednesday, October 11, 2023
Lung cancer, Hepatocellular carcinoma, Melanoma, Breast cancer, AACR, Cell, HNSCC, Cancer, Toxicity, RNA interference, Therapy, Ovarian cancer, Cervical cancer, Head, Glioblastoma, Conference, BRD4, HCC, Poster, Reproductive toxicity, Vaccine

MARLBOROUGH, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced the poster presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts on October 11th -15th.

Key Points: 
  • The first study shows that melanoma cells treated with its PH-894 compound makes them more recognizable to the immune cells.
  • Specifically, the treatment results in an increase in the tumor marker MART-1 (Melanoma tumor-associated antigen) allowing for better recognition and potentially increased killing by T cells.
  • Local treatment with PH-894 presents a strategy to decrease BRD4 expression and upregulate MART-1 expression to increase immune response to cancer cells while reducing toxicities associated with systemic therapies.
  • The second study demonstrates the effectiveness of PH-894 as an antitumor cytotoxic agent (directly killing tumor cells).

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Retrieved on: 
Tuesday, October 10, 2023
Bevacizumab, Q&A, Therapy, Webcast, Hepatocellular carcinoma, HCC, Pharmaceutical industry, Online shopping, Tempest

ET on Wednesday, October 11, 2023.

Key Points: 
  • ET on Wednesday, October 11, 2023.
  • To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call.
  • The live webcast and audio archive of the presentation may be accessed on the investor section of the Tempest website at https://ir.tempesttx.com/ .
  • The webcast will be available for replay for 30 days.

Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023

Retrieved on: 
Wednesday, October 11, 2023
MSD, Congress, Senior, Hepatocellular carcinoma, Abstract, Pembrolizumab, Trial of the century, Bristol Myers Squibb, Merck & Co., Safety, Lung cancer, FR, Endometrial cancer, LEAP, Cancer, Fallopian tube cancer, Patient, FDA, ESMO, Oncology, Ovarian cancer, Meta-analysis, Merck, Research, Science, Lenvatinib, European Society for Medical Oncology, ADC, Pharmaceutical industry, Eisai

We also look forward to sharing data for lenvatinib and from our pipeline, as well as engaging in critical scientific exchange with the community in service of moving oncology research forward."

Key Points: 
  • We also look forward to sharing data for lenvatinib and from our pipeline, as well as engaging in critical scientific exchange with the community in service of moving oncology research forward."
  • A network meta-analysis of lenvatinib versus key comparators as first-line treatment for patients with unresectable hepatocellular carcinoma will also be presented during a poster session (Presentation: #1007P).
  • These abstracts will be made available via the ESMO website on Monday, October 16, 2023, at 12:05 AM CEST.
  • In June 2021, Eisai and Bristol Myers Squibb entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of FZEC.